- Home
- HOOK vs GSIW Comparison
HOOK vs GSIW Comparison
Compare HOOK & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- GSIW
- Stock Information
- Founded
- HOOK 2011
- GSIW 2016
- Country
- HOOK United States
- GSIW Hong Kong
- Employees
- HOOK N/A
- GSIW N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- HOOK Health Care
- GSIW
- Exchange
- HOOK Nasdaq
- GSIW Nasdaq
- Market Cap
- HOOK 9.3M
- GSIW 8.3M
- IPO Year
- HOOK 2019
- GSIW 2023
- Fundamental
- Price
- HOOK $1.59
- GSIW $0.72
- Analyst Decision
- HOOK Buy
- GSIW
- Analyst Count
- HOOK 4
- GSIW 0
- Target Price
- HOOK $10.67
- GSIW N/A
- AVG Volume (30 Days)
- HOOK 207.3K
- GSIW 2.0M
- Earning Date
- HOOK 05-15-2025
- GSIW 12-31-2024
- Dividend Yield
- HOOK N/A
- GSIW N/A
- EPS Growth
- HOOK N/A
- GSIW N/A
- EPS
- HOOK N/A
- GSIW N/A
- Revenue
- HOOK $9,351,000.00
- GSIW $1,313,795.00
- Revenue This Year
- HOOK N/A
- GSIW N/A
- Revenue Next Year
- HOOK N/A
- GSIW N/A
- P/E Ratio
- HOOK N/A
- GSIW N/A
- Revenue Growth
- HOOK N/A
- GSIW N/A
- 52 Week Low
- HOOK $0.72
- GSIW $0.35
- 52 Week High
- HOOK $9.09
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- HOOK 59.36
- GSIW 60.23
- Support Level
- HOOK $1.45
- GSIW $0.70
- Resistance Level
- HOOK $1.62
- GSIW $0.77
- Average True Range (ATR)
- HOOK 0.16
- GSIW 0.12
- MACD
- HOOK -0.00
- GSIW 0.00
- Stochastic Oscillator
- HOOK 67.57
- GSIW 48.50
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.